Clinical Trial

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
Protocol Amendment History 3 changes
critical Enrollment closed, study ongoing 2026-08-11
notable Primary completion moved earlier: 2027-05 -> 2024-04-04 2026-08-11
minor Completion moved earlier: 2028-05 -> 2027-04-04 2026-08-11
Trial Details
NCT Number NCT00935090
Lead Sponsor Barbara Ann Karmanos Cancer Institute
Collaborators: National Cancer Institute (NCI)
Conditions Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms +1 more
Start Date 2009-09
Primary Completion 2024-04-04 (estimated)
Study Completion 2027-04-04 (estimated)
Updated on ClinicalTrials.gov 2026-08-10